vs

Side-by-side financial comparison of Dayforce (DAY) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

Dayforce is the larger business by last-quarter revenue ($481.6M vs $321.1M, roughly 1.5× MADRIGAL PHARMACEUTICALS, INC.). MADRIGAL PHARMACEUTICALS, INC. runs the higher net margin — -18.2% vs -40.9%, a 22.6% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 9.5%).

Dayforce, Inc., formerly Ceridian, is an American human resources software and services company.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

DAY vs MDGL — Head-to-Head

Bigger by revenue
DAY
DAY
1.5× larger
DAY
$481.6M
$321.1M
MDGL
Growing faster (revenue YoY)
MDGL
MDGL
+201.3% gap
MDGL
210.8%
9.5%
DAY
Higher net margin
MDGL
MDGL
22.6% more per $
MDGL
-18.2%
-40.9%
DAY

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
DAY
DAY
MDGL
MDGL
Revenue
$481.6M
$321.1M
Net Profit
$-196.8M
$-58.6M
Gross Margin
Operating Margin
6.3%
-18.6%
Net Margin
-40.9%
-18.2%
Revenue YoY
9.5%
210.8%
Net Profit YoY
-9940.0%
1.4%
EPS (diluted)
$-1.23
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DAY
DAY
MDGL
MDGL
Q4 25
$321.1M
Q3 25
$481.6M
$287.3M
Q2 25
$464.7M
$212.8M
Q1 25
$481.8M
$137.3M
Q4 24
$465.2M
$103.3M
Q3 24
$440.0M
$62.2M
Q2 24
$423.3M
Q1 24
$431.5M
$0
Net Profit
DAY
DAY
MDGL
MDGL
Q4 25
$-58.6M
Q3 25
$-196.8M
$-114.2M
Q2 25
$21.3M
$-42.3M
Q1 25
$14.9M
$-73.2M
Q4 24
$10.8M
$-59.4M
Q3 24
$2.0M
$-107.0M
Q2 24
$-1.8M
Q1 24
$7.1M
$-147.5M
Gross Margin
DAY
DAY
MDGL
MDGL
Q4 25
Q3 25
Q2 25
Q1 25
96.7%
Q4 24
47.0%
Q3 24
45.8%
Q2 24
44.1%
Q1 24
47.6%
Operating Margin
DAY
DAY
MDGL
MDGL
Q4 25
-18.6%
Q3 25
6.3%
-39.7%
Q2 25
9.1%
-22.2%
Q1 25
6.4%
-57.8%
Q4 24
6.1%
-64.8%
Q3 24
4.7%
-187.1%
Q2 24
3.3%
Q1 24
9.4%
Net Margin
DAY
DAY
MDGL
MDGL
Q4 25
-18.2%
Q3 25
-40.9%
-39.8%
Q2 25
4.6%
-19.9%
Q1 25
3.1%
-53.4%
Q4 24
2.3%
-57.5%
Q3 24
0.5%
-172.0%
Q2 24
-0.4%
Q1 24
1.6%
EPS (diluted)
DAY
DAY
MDGL
MDGL
Q4 25
$-2.55
Q3 25
$-1.23
$-5.08
Q2 25
$0.13
$-1.90
Q1 25
$0.09
$-3.32
Q4 24
$0.07
$-2.50
Q3 24
$0.01
$-4.92
Q2 24
$-0.01
Q1 24
$0.04
$-7.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DAY
DAY
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$627.6M
$198.7M
Total DebtLower is stronger
$631.1M
$339.9M
Stockholders' EquityBook value
$2.7B
$602.7M
Total Assets
$8.7B
$1.3B
Debt / EquityLower = less leverage
0.23×
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DAY
DAY
MDGL
MDGL
Q4 25
$198.7M
Q3 25
$627.6M
$295.7M
Q2 25
$625.2M
$186.2M
Q1 25
$557.3M
$183.6M
Q4 24
$579.7M
$100.0M
Q3 24
$494.1M
$232.7M
Q2 24
$465.4M
Q1 24
$392.5M
$622.5M
Total Debt
DAY
DAY
MDGL
MDGL
Q4 25
$339.9M
Q3 25
$631.1M
$339.8M
Q2 25
$631.8M
$118.4M
Q1 25
$632.4M
$118.0M
Q4 24
$1.2B
$117.6M
Q3 24
$1.2B
$117.1M
Q2 24
$1.2B
Q1 24
$1.2B
$116.1M
Stockholders' Equity
DAY
DAY
MDGL
MDGL
Q4 25
$602.7M
Q3 25
$2.7B
$625.7M
Q2 25
$2.7B
$696.0M
Q1 25
$2.6B
$710.6M
Q4 24
$2.5B
$754.4M
Q3 24
$2.6B
$777.2M
Q2 24
$2.5B
Q1 24
$2.4B
$850.8M
Total Assets
DAY
DAY
MDGL
MDGL
Q4 25
$1.3B
Q3 25
$8.7B
$1.4B
Q2 25
$8.5B
$1.0B
Q1 25
$9.5B
$996.6M
Q4 24
$9.1B
$1.0B
Q3 24
$8.1B
$1.1B
Q2 24
$9.0B
Q1 24
$10.8B
$1.1B
Debt / Equity
DAY
DAY
MDGL
MDGL
Q4 25
0.56×
Q3 25
0.23×
0.54×
Q2 25
0.23×
0.17×
Q1 25
0.24×
0.17×
Q4 24
0.47×
0.16×
Q3 24
0.47×
0.15×
Q2 24
0.49×
Q1 24
0.50×
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DAY
DAY
MDGL
MDGL
Operating Cash FlowLast quarter
$31.2M
$-133.5M
Free Cash FlowOCF − Capex
$-133.8M
FCF MarginFCF / Revenue
-41.7%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DAY
DAY
MDGL
MDGL
Q4 25
$-133.5M
Q3 25
$31.2M
$79.8M
Q2 25
$112.7M
$-47.1M
Q1 25
$49.6M
$-88.9M
Q4 24
$81.0M
$-104.5M
Q3 24
$91.8M
$-67.0M
Q2 24
$99.2M
Q1 24
$9.1M
$-149.2M
Free Cash Flow
DAY
DAY
MDGL
MDGL
Q4 25
$-133.8M
Q3 25
$79.0M
Q2 25
Q1 25
Q4 24
$-104.7M
Q3 24
$-67.8M
Q2 24
Q1 24
$-149.5M
FCF Margin
DAY
DAY
MDGL
MDGL
Q4 25
-41.7%
Q3 25
27.5%
Q2 25
Q1 25
Q4 24
-101.3%
Q3 24
-109.0%
Q2 24
Q1 24
Capex Intensity
DAY
DAY
MDGL
MDGL
Q4 25
0.1%
Q3 25
0.3%
Q2 25
0.0%
Q1 25
0.0%
Q4 24
0.2%
Q3 24
1.3%
Q2 24
Q1 24
Cash Conversion
DAY
DAY
MDGL
MDGL
Q4 25
Q3 25
Q2 25
5.29×
Q1 25
3.33×
Q4 24
7.50×
Q3 24
45.90×
Q2 24
Q1 24
1.28×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DAY
DAY

Dayforce Recurring$333.0M69%
Cloud And Bureau Professional Services And Other$78.5M16%
Float$42.2M9%
Powerpay Recurring$19.7M4%
Other Recurring$8.2M2%

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons